Search Results - "JANKU, Filip"

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients by Janku, Filip

“…•Many PI3K inhibitors have been developed, but few have received regulatory approval.•As PI3K inhibitors have modest activity alone, rational combinations are…”
Get full text

Targeting the PI3K pathway in cancer: are we making headway? by Janku, Filip, Yap, Timothy A., Meric-Bernstam, Funda

“…Key Points The PI3K–AKT–mTOR signalling pathway, which controls multiple cellular processes including metabolism, motility, proliferation, growth, and…”
Get full text

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway by POLIVKA, Jiri, JANKU, Filip

“…Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and…”
Get full text

Tumor heterogeneity in the clinic: is it a real problem? by Janku, Filip

“…Tumor heterogeneity is one of the major problems limiting the efficacy of targeted therapies and compromising treatment outcomes. A better understanding of…”
Get full text

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages by Emile, Jean-François, Abla, Oussama, Fraitag, Sylvie, Horne, Annacarin, Haroche, Julien, Donadieu, Jean, Requena-Caballero, Luis, Jordan, Michael B., Abdel-Wahab, Omar, Allen, Carl E., Charlotte, Frédéric, Diamond, Eli L., Egeler, R.Maarten, Fischer, Alain, Herrera, Juana Gil, Henter, Jan-Inge, Janku, Filip, Merad, Miriam, Picarsic, Jennifer, Rodriguez-Galindo, Carlos, Rollins, Barret J., Tazi, Abdellatif, Vassallo, Robert, Weiss, Lawrence M.

“…The histiocytoses are rare disorders characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs…”
Get full text

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening by Adashek, Jacob J, Janku, Filip, Kurzrock, Razelle

“…With the addition of molecular testing to the oncologist's diagnostic toolbox, patients have benefitted from the successes of gene- and immune-directed…”
Get full text

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era by Goyal, Gaurav, Heaney, Mark L., Collin, Matthew, Cohen-Aubart, Fleur, Vaglio, Augusto, Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Girschikofsky, Michael, Jacobsen, Eric D., Toyama, Kazuhiro, Goodman, Aaron M., Hendrie, Paul, Cao, Xin-xin, Estrada-Veras, Juvianee I., Shpilberg, Ofer, Abdo, André, Kurokawa, Mineo, Dagna, Lorenzo, McClain, Kenneth L., Mazor, Roei D., Picarsic, Jennifer, Janku, Filip, Go, Ronald S., Haroche, Julien, Diamond, Eli L.

“…Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK…”
Get full text

Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma by Mellinghoff, Ingo K, Ellingson, Benjamin M, Touat, Mehdi, Maher, Elizabeth, De La Fuente, Macarena I, Holdhoff, Matthias, Cote, Gregory M, Burris, Howard, Janku, Filip, Young, Robert J, Huang, Raymond, Jiang, Liewen, Choe, Sung, Fan, Bin, Yen, Katharine, Lu, Min, Bowden, Chris, Steelman, Lori, Pandya, Shuchi S, Cloughesy, Timothy F, Wen, Patrick Y

“…Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor…”
Get full text

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial by Mellinghoff, Ingo K, Penas-Prado, Marta, Peters, Katherine B, Burris, 3rd, Howard A, Maher, Elizabeth A, Janku, Filip, Cote, Gregory M, de la Fuente, Macarena I, Clarke, Jennifer L, Ellingson, Benjamin M, Chun, Saewon, Young, Robert J, Liu, Hua, Choe, Sung, Lu, Min, Le, Kha, Hassan, Islam, Steelman, Lori, Pandya, Shuchi S, Cloughesy, Timothy F, Wen, Patrick Y

“…Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is…”
Get full text

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials by Meric-Bernstam, Funda, Brusco, Lauren, Shaw, Kenna, Horombe, Chacha, Kopetz, Scott, Davies, Michael A, Routbort, Mark, Piha-Paul, Sarina A, Janku, Filip, Ueno, Naoto, Hong, David, De Groot, John, Ravi, Vinod, Li, Yisheng, Luthra, Raja, Patel, Keyur, Broaddus, Russell, Mendelsohn, John, Mills, Gordon B

“…We report the experience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testing protocol, including the frequency of…”
Get full text

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease by Diamond, Eli L., Dagna, Lorenzo, Hyman, David M., Cavalli, Giulio, Janku, Filip, Estrada-Veras, Juvianee, Ferrarini, Marina, Abdel-Wahab, Omar, Heaney, Mark L., Scheel, Paul J., Feeley, Nancy K., Ferrero, Elisabetta, McClain, Kenneth L., Vaglio, Augusto, Colby, Thomas, Arnaud, Laurent, Haroche, Julien

“…Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAFV600E…”
Get full text

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative by TSIMBERIDOU, Apostolia-Maria, ISKANDER, Nancy G, YANG YE, SIJIN WEN, BERRY, Donald, KURZROCK, Razelle, HONG, David S, WHELER, Jennifer J, FALCHOOK, Gerald S, SIQING FU, PIHA-PAUL, Sarina, NAING, Aung, JANKU, Filip, LUTHRA, Rajyalakshmi

“…We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein,…”
Get full text

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial by How, Jeffrey A., Jazaeri, Amir A., Soliman, Pamela T., Fleming, Nicole D., Gong, Jing, Piha-Paul, Sarina A., Janku, Filip, Stephen, Bettzy, Naing, Aung

“…Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case…”
Get full text

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants by Smith, Bryan D., Kaufman, Michael D., Lu, Wei-Ping, Gupta, Anu, Leary, Cynthia B., Wise, Scott C., Rutkoski, Thomas J., Ahn, Yu Mi, Al-Ani, Gada, Bulfer, Stacie L., Caldwell, Timothy M., Chun, Lawrence, Ensinger, Carol L., Hood, Molly M., McKinley, Arin, Patt, William C., Ruiz-Soto, Rodrigo, Su, Ying, Telikepalli, Hanumaiah, Town, Ajia, Turner, Benjamin A., Vogeti, Lakshminarayana, Vogeti, Subha, Yates, Karen, Janku, Filip, Abdul Razak, Albiruni Ryan, Rosen, Oliver, Heinrich, Michael C., Flynn, Daniel L.

“…Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms,…”
Get full text

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study by Wheler, Jennifer J, Janku, Filip, Naing, Aung, Li, Yali, Stephen, Bettzy, Zinner, Ralph, Subbiah, Vivek, Fu, Siqing, Karp, Daniel, Falchook, Gerald S, Tsimberidou, Apostolia M, Piha-Paul, Sarina, Anderson, Roosevelt, Ke, Danxia, Miller, Vincent, Yelensky, Roman, Lee, J Jack, Hong, David S, Kurzrock, Razelle

“…Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve…”
Get full text

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications by Churi, Chaitanya R, Shroff, Rachna, Wang, Ying, Rashid, Asif, Kang, HyunSeon C, Weatherly, Jacqueline, Zuo, Mingxin, Zinner, Ralph, Hong, David, Meric-Bernstam, Funda, Janku, Filip, Crane, Christopher H, Mishra, Lopa, Vauthey, Jean-Nicholas, Wolff, Robert A, Mills, Gordon, Javle, Milind

“…Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing (NGS)…”
Get full text

Associations between the gut microbiome and fatigue in cancer patients by Hajjar, Joud, Mendoza, Tito, Zhang, Liangliang, Fu, Siqing, Piha-Paul, Sarina A., Hong, David S., Janku, Filip, Karp, Daniel D., Ballhausen, Alexej, Gong, Jing, Zarifa, Abdulrazzak, Peterson, Christine B., Meric-Bernstam, Funda, Jenq, Robert, Naing, Aung

“…Fatigue is the most prevalent symptom of cancer and its treatments. Changes in the intestinal microbiome have been identified in chronic fatigue syndrome and…”
Get full text

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers by Möhrmann, Lino, Huang, Helen J, Hong, David S, Tsimberidou, Apostolia M, Fu, Siqing, Piha-Paul, Sarina A, Subbiah, Vivek, Karp, Daniel D, Naing, Aung, Krug, Anne, Enderle, Daniel, Priewasser, Tina, Noerholm, Mikkel, Eitan, Erez, Coticchia, Christine, Stoll, Georg, Jordan, Lisa-Marie, Eng, Cathy, Kopetz, E Scott, Skog, Johan, Meric-Bernstam, Funda, Janku, Filip

“…Blood-based liquid biopsies offer easy access to genomic material for molecular diagnostics in cancer. Commonly used cell-free DNA (cfDNA) originates from…”
Get full text

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers by Groisberg, Roman, Hong, David S, Roszik, Jason, Janku, Filip, Tsimberidou, Apostolia M, Javle, Milind, Meric-Bernstam, Funda, Subbiah, Vivek

“…The European Society for Medical Oncology defines rare cancers as 5 or fewer cases per 100,000 persons per year. For many rare cancers, no standard of care…”
Get full text

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations by JANKU, Filip, WHELER, Jennifer J, LUTHRA, Rajyalakshmi, LEE, J. Jack, LU, Karen H, KURZROCK, Razelle, WESTIN, Shannon N, MOULDER, Stacy L, NAING, Aung, TSIMBERIDOU, Apostolia M, SIQING FU, FALCHOOK, Gerald S, HONG, David S, GARRIDO-LAGUNA, Ignacio

“…Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant…”
Get full text